ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026

Cost-effectiveness analysis of immune checkpoint inhibitors versus platinum-based doublet chemotherapy in the first-line treatment of advanced non-small-cell lung cancer with High PD-L1 expression in Japan.

Chanon Nusawat et al.PubMed ↗Publisher ↗

No numbers read from the abstract.